Finally, our study, together with other studies, indicated that the cytoplasmic domain of PD-L1 regulates PD-L1 glycosylation, degradation, binding with PD-1, and so on through various mechanisms, making it an attractive target for immunotherapy and blockade of PD-L1-related cancer signaling. This evidence concerns the gene CD274 and cancer.